Tempus AI, Inc. (NASDAQ:TEM) CEO Sells $4,580,221.32 in Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric P. Lefkofsky sold 85,788 shares of the business's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $53.39, for a total transaction of $4,580,221.32. Following the transaction, the chief executive officer now directly owns 5,771,787 shares in the company, valued at approximately $308,155,707.93. The trade was a 1.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Tempus AI Stock Performance

Shares of TEM traded down $3.44 during mid-day trading on Friday, hitting $51.40. 12,994,864 shares of the company's stock were exchanged, compared to its average volume of 9,294,415. The stock's 50-day moving average is $44.38 and its 200-day moving average is $47.46. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TEM. Bank of America increased their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a research note on Friday, December 13th. Piper Sandler reiterated a "neutral" rating and issued a $70.00 price objective (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Stifel Nicolaus downgraded Tempus AI from a "buy" rating to a "hold" rating and lifted their target price for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Guggenheim started coverage on Tempus AI in a report on Monday, December 9th. They set a "buy" rating and a $74.00 price target for the company. Finally, Needham & Company LLC restated a "buy" rating and issued a $56.00 price objective on shares of Tempus AI in a report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $56.36.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP purchased a new position in shares of Tempus AI in the 2nd quarter valued at about $4,861,000. Fred Alger Management LLC acquired a new stake in shares of Tempus AI in the 2nd quarter valued at $2,167,000. Squarepoint Ops LLC acquired a new stake in shares of Tempus AI in the 2nd quarter valued at $633,000. Employees Retirement System of Texas purchased a new stake in shares of Tempus AI during the 2nd quarter worth $1,039,000. Finally, Dragoneer Investment Group LLC acquired a new position in shares of Tempus AI during the second quarter worth $1,750,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.